Achillion announces additional phase 2 results including 100% SVR24 for genotype 1 HCV
Achillion Pharmaceuticals announced updated results from the ongoing phase 2 ‘604 Study' being conducted by Alios BioPharma, a Janssen Company. These results demonstrate that the triple combination of simeprevir, odalasvir and AL-335 has the ability to shorten treatment duration. April 22, 2017